Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-1530 in Relapsed or Refractory Mantle Cell Lymphoma
CTR20201441Phase 2Terminated
- Sponsor
- Beijing Sailintai Pharmaceutical Technology
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CT-1530 in mantle cell lymphoma (MCL), sponsored by Beijing Sailintai Pharmaceutical Technology. Started Jul 2020; status: terminated.
02
Drugs
CT-1530
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20201441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201441.